{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:36:42Z","timestamp":1794577002539,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s40265-019-01130-z","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T09:03:48Z","timestamp":1558947828000},"page":"1031-1036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment"],"prefix":"10.1007","volume":"79","author":[{"given":"Emily M.","family":"Schehlein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,27]]},"reference":[{"key":"1130_CR1","first-page":"887","volume":"82","author":"S Kingman","year":"2004","unstructured":"Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ. 2004;82:887\u20138.","journal-title":"Bull World Health Organ"},{"key":"1130_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1130_CR3","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"Y-C Tham","year":"2014","unstructured":"Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081\u201390.","journal-title":"Ophthalmology"},{"key":"1130_CR4","doi-asserted-by":"crossref","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group (2002) Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol (Chicago, Ill 1960) 120:1268\u201379.","DOI":"10.1001\/archopht.120.10.1268"},{"issue":"8","key":"1130_CR5","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/archopht.126.8.1030","volume":"126","author":"Balwantray C. Chauhan","year":"2008","unstructured":"Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE (2008) Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol (Chicago, Ill 1960) 126:1030\u20131036.","journal-title":"Archives of Ophthalmology"},{"key":"1130_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1089\/jop.2017.0051","volume":"33","author":"MGJ Trese","year":"2017","unstructured":"Trese MGJ, Lewis AW, Blachley TS, Stein JD, Moroi SE. Changing initial glaucoma medical therapy increases healthcare resource utilization. J Ocul Pharmacol Ther. 2017;33:591\u20137.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"1130_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"Michael A. Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (Chicago, Ill 1960) 120:701\u2013730.","journal-title":"Archives of Ophthalmology"},{"key":"1130_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0161-6420(99)90147-1","volume":"106","author":"DC Musch","year":"1999","unstructured":"Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999;106:653\u201362.","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"1130_CR9","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","volume":"53","author":"GF Schwartz","year":"2008","unstructured":"Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl 1):S57\u201368.","journal-title":"Surv Ophthalmol"},{"key":"1130_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1001\/jamaophthalmol.2015.5479","volume":"134","author":"AJ Prager","year":"2016","unstructured":"Prager AJ, Liebmann JM, Cioffi GA, Blumberg DM. Self-reported function, health resource use, and total health care costs among medicare beneficiaries with glaucoma. JAMA Ophthalmol. 2016;134:357\u201365.","journal-title":"JAMA Ophthalmol"},{"key":"1130_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd1719","volume":"4","author":"BK Mueller","year":"2005","unstructured":"Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 2005;4:387\u201398.","journal-title":"Nat Rev Drug Discov"},{"key":"1130_CR12","doi-asserted-by":"crossref","unstructured":"Abu-Hassan DW, Acott TS, Kelley MJ. The trabecular meshwork: a basic review of form and function. J Ocul Biol. 2014;2(1).","DOI":"10.13188\/2334-2838.1000017"},{"key":"1130_CR13","first-page":"1029","volume":"42","author":"PV Rao","year":"2001","unstructured":"Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42:1029\u201337.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1130_CR14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/40187","volume":"389","author":"M Uehata","year":"1997","unstructured":"Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990\u20134.","journal-title":"Nature"},{"key":"1130_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00063030-200721030-00004","volume":"21","author":"VP Rao","year":"2007","unstructured":"Rao VP, Epstein DL. Rho GTPase\/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs. 2007;21:167\u201377.","journal-title":"BioDrugs"},{"key":"1130_CR16","first-page":"137","volume":"42","author":"M Honjo","year":"2001","unstructured":"Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, Narumiya S, Honda Y. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137\u201344.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1130_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/IJG.0b013e3182952213","volume":"24","author":"R-F Wang","year":"2015","unstructured":"Wang R-F, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24:51\u20134.","journal-title":"J Glaucoma"},{"key":"1130_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3109\/02713683.2013.874444","volume":"39","author":"T Isobe","year":"2014","unstructured":"Isobe T, Mizuno K, Kaneko Y, Ohta M, Koide T, Tanabe S. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res. 2014;39:813\u201322.","journal-title":"Curr Eye Res"},{"key":"1130_CR19","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1167\/iovs.05-1617","volume":"48","author":"H Tokushige","year":"2007","unstructured":"Tokushige H, Inatani M, Nemoto S, Sakaki H, Katayama K, Uehata M, Tanihara H. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216\u201322.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1130_CR20","doi-asserted-by":"publisher","first-page":"19640","DOI":"10.1038\/srep19640","volume":"6","author":"Y Kaneko","year":"2016","unstructured":"Kaneko Y, Ohta M, Inoue T, Mizuno K, Isobe T, Tanabe S, Tanihara H. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm\u2019s canal endothelial cells. Sci Rep. 2016;6:19640.","journal-title":"Sci Rep"},{"key":"1130_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156:731\u20136.","journal-title":"Am J Ophthalmol"},{"key":"1130_CR22","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Fukushima A, Suganami H, Araie M. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94:e26\u201334.","journal-title":"Acta Ophthalmol"},{"key":"1130_CR23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","volume":"133","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, Araie M. Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133:755\u201361.","journal-title":"JAMA Ophthalmol"},{"key":"1130_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ophtha.2014.08.022","volume":"122","author":"J Bacharach","year":"2015","unstructured":"Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122:302\u20137.","journal-title":"Ophthalmology"},{"key":"1130_CR25","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1080\/02713683.2016.1250276","volume":"42","author":"E Terao","year":"2017","unstructured":"Terao E, Nakakura S, Fujisawa Y, Fujio Y, Matsuya K, Kobayashi Y, Tabuchi H, Yoneda T, Fukushima A, Kiuchi Y. Time course of conjunctival hyperemia induced by a rho-kinase inhibitor anti-glaucoma eye drop: ripasudil 0.4. Curr Eye Res. 2017;42:738\u201342.","journal-title":"Curr Eye Res"},{"key":"1130_CR26","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","volume":"131","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131:1288\u201395.","journal-title":"JAMA Ophthalmol"},{"key":"1130_CR27","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1167\/iovs.15-17887","volume":"56","author":"N Okumura","year":"2015","unstructured":"Okumura N, Okazaki Y, Inoue R, Nakano S, Fullwood NJ, Kinoshita S, Koizumi N. Rho-associated kinase inhibitor eye drop (Ripasudil) transiently alters the morphology of corneal endothelial cells. Invest Ophthalmol Vis Sci. 2015;56:7560\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1130_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/ICO.0000000000001209","volume":"36","author":"G Moloney","year":"2017","unstructured":"Moloney G, Petsoglou C, Ball M, Kerdraon Y, Hollhumer R, Spiteri N, Beheregaray S, Hampson J, D\u2019Souza M, Devasahayam RN. Descemetorhexis without grafting for fuchs endothelial dystrophy-supplementation with topical ripasudil. Cornea. 2017;36:642\u20138.","journal-title":"Cornea"},{"key":"1130_CR29","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1167\/iovs.13-13842","volume":"55","author":"K Yamamoto","year":"2014","unstructured":"Yamamoto K, Maruyama K, Himori N, Omodaka K, Yokoyama Y, Shiga Y, Morin R, Nakazawa T. The novel Rho kinase (ROCK) inhibitor K-115: a new candidate drug for neuroprotective treatment in glaucoma. Invest Ophthalmol Vis Sci. 2014;55:7126\u201336.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"1130_CR30","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.bmcl.2016.03.104","volume":"26","author":"Jill M. Sturdivant","year":"2016","unstructured":"Sturdivant JM, Royalty SM, Lin C-W, Moore LA, Yingling JD, Laethem CL, Sherman B, Heintzelman GR, Kopczynski CC, deLong MA (2016) Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorg Med Chem Lett. \nhttps:\/\/doi.org\/10.1016\/j.bmcl.2016.03.104\n\n.","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"1130_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejphar.2016.04.002","volume":"787","author":"Guorong Li","year":"2016","unstructured":"Li G, Mukherjee D, Navarro I, et al (2016) Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur J Pharmacol. \nhttps:\/\/doi.org\/10.1016\/j.ejphar.2016.04.002\n\n.","journal-title":"European Journal of Pharmacology"},{"key":"1130_CR32","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.1167\/iovs.16-20189","volume":"57","author":"R Ren","year":"2016","unstructured":"Ren R, Li G, Le TD, Kopczynski C, Stamer WD, Gong H. Netarsudil increases outflow facility in human eyes through multiple mechanisms. Invest Ophthalmol Vis Sci. 2016;57:6197\u2013209.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1130_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116\u201327.","journal-title":"Am J Ophthalmol"},{"key":"1130_CR34","doi-asserted-by":"publisher","first-page":"980-5.e1","DOI":"10.1016\/j.ajo.2015.01.026","volume":"159","author":"B Levy","year":"2015","unstructured":"Levy B, Ramirez N, Novack GD, Kopczynski C. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. Am J Ophthalmol. 2015;159:980-5.e1.","journal-title":"Am J Ophthalmol"},{"key":"1130_CR35","unstructured":"Aerie Pharmaceuticals Inc (2017) Aerie pharmaceuticals reports positive RoclatanTM (netarsudil\/latanoprost ophthalmic solution) 0.02%\/0.005% phase 3 topline efficacy results. \nhttps:\/\/www.businesswire.com\/news\/home\/20170524006043\/en\/Aerie-Pharmaceuticals-Reports-Positive-RoclatanTM-netarsudillatanoprost-ophthalmic\n\n.\u00a0"},{"key":"1130_CR36","unstructured":"Bacharach, J., Khouri, A.S., Heah, T., Kopczynski C, Lewis R (2017) A double-masked, randomized, multi-center, active-controlled, parallel group, 6-month study assessing the ocular hypotensive efficacy and safety of netarsudil ophthalmic solution, 0.02% QD compared to timolol maleate ophthalmic solution, 0.5% BID in patie. Am Acad Optom Abst E351:(Oct 11\u201314, Chicago)."},{"key":"1130_CR37","unstructured":"Lewis R a, Levy B, Ramirez N, C Kopczynski C, Usner DW, Novack GD (2015) Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol Bjophthalmol 2015:306778."},{"key":"1130_CR38","unstructured":"Aerie Pharmaceuticals Inc (2016) RoclatanTM mercury 2 phase 3 topline results. \nhttp:\/\/investors.aeriepharma.com\/static-files\/fb9a0c3f-7255-4b50-97b2-450a2ba5d139\n\n."},{"key":"1130_CR39","doi-asserted-by":"publisher","first-page":"834-41.e1","DOI":"10.1016\/j.ajo.2011.04.012","volume":"152","author":"RD Williams","year":"2011","unstructured":"Williams RD, Novack GD, van Haarlem T, Kopczynski C. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011;152:834-41.e1.","journal-title":"Am J Ophthalmol"},{"key":"1130_CR40","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1111\/aos.12641","volume":"93","author":"T Inoue","year":"2015","unstructured":"Inoue T, Tanihara H, Tokushige H, Araie M. Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol. 2015;93:e393\u20135.","journal-title":"Acta Ophthalmol"},{"key":"1130_CR41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.expneurol.2007.02.002","volume":"205","author":"H Sagawa","year":"2007","unstructured":"Sagawa H, Terasaki H, Nakamura M, Ichikawa M, Yata T, Tokita Y, Watanabe M. A novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats. Exp Neurol. 2007;205:230\u201340.","journal-title":"Exp Neurol"},{"key":"1130_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5005\/jp-journals-10028-1226","volume":"11","author":"S Phulke","year":"2017","unstructured":"Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced Glaucoma: an avoidable irreversible blindness. J Curr glaucoma Pract. 2017;11:67\u201372.","journal-title":"J Curr glaucoma Pract"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01130-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01130-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01130-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T23:30:22Z","timestamp":1590449422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01130-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,27]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1130"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01130-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,27]]},"assertion":[{"value":"27 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Alan Robin serves as Executive Vice President of the American Glaucoma Society. Dr. Emily Schehlein has no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}